Condition
Pharmacokinetics of Darexaban and Metabolites
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT01405989Phase 1CompletedPrimary
To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)
NCT01406002Phase 1CompletedPrimary
To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)
Showing all 2 trials